GlassScriptPhysician profile
Donna C Smith
NPI 1942594833
$5,238.67
in general payments reported to CMS, 2019-2025
34 companies · $665 in 2025
The $665 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $916 · 2022: $1,031 · 2023: $1,281 · 2024: $1,346 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,212.10 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $933.60 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $837.34 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $483.32 | 2021-2025 | |
| Lilly USA, LLC | $431.74 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $337.70 | 2023-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.50 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $215.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $159.78 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.57 | 2021-2024 | Jardiance |
| Pfizer INC. | $141.66 | 2021-2024 | |
| Boston Scientific Corporation | $136.16 | 2024-2025 | Watchman Flx |
| Gilead Sciences, INC. | $119.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $112.16 | 2021-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Abbott Laboratories | $112.03 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $92.47 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $87.61 | 2022-2023 | Azstarys |
| Janssen Biotech, INC. | $56.77 | 2025 | Tremfya, Simponi, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $55.24 | 2021-2022 | |
| Amgen INC. | $51.44 | 2023-2024 | Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $50.75 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $47.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $37.37 | 2021-2023 | |
| Exact Sciences Corporation | $34.72 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $32.45 | 2023 | Shingrix, Arexvy |
| Medicure Pharma INC. | $28.99 | 2021 | |
| Tris Pharma INC | $22.82 | 2023 | Dyanavel Xr |
| Sanofi Pasteur INC. | $21.51 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.32 | 2023 | Quviviq |
| Sobi, INC | $20.01 | 2022 | |
| Mylan Specialty L.P. | $17.28 | 2021 | |
| Cognoa, INC. | $16.88 | 2022 | |
| Endo USA, INC. | $16.77 | 2025 | Xiaflex, Aveed |
| Esperion Therapeutics, INC. | $13.72 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.